Arvinas Stock Clears Technical Benchmark With 80-Plus Relative Strength Rating

The Relative Strength Rating for Arvinas (ARVN) entered a new percentile Thursday, with a rise from 79 to 84. Is Arvinas stock on your watchlist?


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

IBD’s proprietary RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock’s price performance over the trailing 52 weeks matches up against other publicly traded companies.

Over 100 years of market history reveals that the best stocks tend to have an 80 or higher RS Rating as they begin their biggest price moves.

Looking For The Best Stocks To Buy And Watch? Start Here

Is Arvinas Stock A Buy?

Arvinas stock has climbed more than 5% past a 55.05 entry in a second-stage consolidation, meaning it’s now out of a proper buy range. Look for Arvinas stock to create a new buying opportunity like a three-weeks-tight pattern or a pullback to the 50-day or 10-week moving average.

While EPS growth declined in the prior quarter from 0% to -76%, revenue improved to -55%, up from -75% in the prior report. The next quarterly results for the New Haven, Conn.-based biopharmaceutical company are expected on or around April 28.

Arvinas stock holds the No. 208 rank among its peers in the Medical-Biomed/Biotech industry group. Alexion Pharmaceuticals (ALXN) and Halozyme Therapeutics (HALO) are also among the group’s highest-rated stocks.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength


Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button